A phase 3, multi-center, open-label, randomized study of oral ABL001 versus bosutinib in patients with Chronic Myelogenous Leukemia in chronic phase (CML-CP), previously treated with 2 or more tyrosine kinase inhibitors
2022-06-27
عنوان الدراسة
A phase 3, multi-center, open-label, randomized study of oral ABL001 versus bosutinib in patients with Chronic Myelogenous Leukemia in chronic phase (CML-CP), previously treated with 2 or more tyrosine kinase inhibitors
داعم الدراسة
Novartis
دواء الدراسة
ABL001 (asciminib)
رقم بروتوكول الدراسة
CABL001A2301
حالة الدراسة
Ongoing
موقع الدراسة
KFSH&RC-R
مرحلة الدراسة
3
评论与建议
如对政府服务有任何咨询或意见,请填写所需信息。